RESUMO
Cardiac single photon emission computed tomography using 99mTc-bone avid tracers allows for an accurate noninvasive diagnosis of transthyretin (ATTR) cardiac amyloidosis, a historically underdiagnosed disease. This imaging is recommended in select populations who demonstrate clinical and imaging features of infiltrative cardiomyopathy. It is imperative to concomitantly assess for light chain (AL) cardiac amyloidosis independent of radionuclide scintigraphy for timely management of AL amyloidosis, a deadly disease requiring urgent therapy. Clinical judgement is also key and in some select scenarios an endomyocardial biopsy may be needed even after a noninvasive evaluation.
Assuntos
Amiloidose , Cardiomiopatias , Humanos , Cardiomiopatias/diagnóstico por imagem , Pré-Albumina , Amiloidose/diagnóstico por imagem , Cintilografia , Coração , Compostos RadiofarmacêuticosRESUMO
Technetium-labeled cardiac scintigraphy (i.e., Tc-PYP scan) has been repurposed for the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM). Validated in cohorts of patients with heart failure and echocardiographic and/or cardiac magnetic resonance imaging findings suggestive of cardiac amyloidosis, cardiac scintigraphy can confirm the diagnosis of ATTR-CM only when combined with blood and urine testing to exclude a monoclonal protein. Multisocietal guidelines support the nonbiopsy diagnosis of ATTR-CM using cardiac scintigraphy, yet emphasize its use in the appropriate clinical context and the crucial need to rule out light chain amyloid cardiomyopathy. Although increased awareness of ATTR-CM and the advent of effective therapy have led to rapid adoption of diagnostic scintigraphy, there is heterogeneity in adherence to consensus guidelines. This perspective outlines clinical scenarios wherein findings on technetium-labeled cardiac scintigraphy have been misinterpreted, reviews causes of false-negative and false-positive results, and provides strategies to avoid costly and potentially fatal misdiagnoses.